Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Voting Common Stock, par value $0.0001 per share
-
Shares outstanding
-
5,381,598
-
Total 13F shares
-
1,618,304
-
Share change
-
-76,340
-
Total reported value
-
$64,472,927
-
Price per share
-
$39.84
-
Number of holders
-
32
-
Value change
-
+$11,786,170
-
Number of buys
-
19
-
Number of sells
-
9
Institutional Holders of Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) as of Q4 2024
As of 31 Dec 2024,
Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,618,304 shares.
The largest 10 holders included
ADAGE CAPITAL PARTNERS GP, L.L.C., EcoR1 Capital, LLC, Deep Track Capital, LP, Vivo Capital, LLC, VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, HHLR ADVISORS, LTD., Trexquant Investment LP, Ikarian Capital, LLC, and OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC).
This page lists
33
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.